LYNDHURST, N.J., Nov 28, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing,
information and services, announced that it is scheduled to speak at the
Merrill Lynch Health Services Investor Conference on Tuesday, November 29,
2005, at The Waldorf Astoria Hotel in New York City. The Quest Diagnostics
presentation is scheduled to begin at 8:45 a.m. Eastern Time.
During the conference, the company will reiterate its 2005 guidance of
revenue growth to approach 5.5%, operating income to approach 18% of revenues,
and earnings per diluted share of between $2.61 and $2.64.
The presentation will be webcast live during the conference and will be
available to registered investors on the following site:
http://www.wsw.com/webcast/ml48/dgx/ and to the public on:
http://www.questdiagnostics.com. In addition, the archived webcast will be
available starting five minutes after the presentation and will remain
available until December 13, 2005.
Quest Diagnostics is the leading provider of diagnostic testing,
information and services that patients and doctors need to make better
healthcare decisions. The company offers the broadest access to diagnostic
testing services through its national network of laboratories and patient
service centers, and provides interpretive consultation through its extensive
medical and scientific staff. Quest Diagnostics is a pioneer in developing
innovative new diagnostic tests and advanced healthcare information technology
solutions that help improve patient care. Additional company information is
available at: http://www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results and
outcomes to be materially different. Certain of these risks and uncertainties
may include, but are not limited to, competitive environment, changes in
government regulations, changing relationships with customers, payers,
suppliers and strategic partners and other factors described in the Quest
Diagnostics Incorporated 2004 Form 10-K and subsequent filings.
SOURCE Quest Diagnostics Incorporated
Investors - Laure Park, +1-201-393-5030;
or Media - Gary Samuels, +1-201-393-5700,
both of Quest Diagnostics Incorporated